Mylaine Riobe MD, FABOIM, FACOG
Riobe Institute of Integrative Medicine
Dr. Riobe''s undergraduate studies were completed at Columbia University/Columbia College in NYC where she grew up. She obtained her medical degree at NY Medical College and completed her residency in Obstetrics and Gynecology at Medical College of Pennsylvania and the University of South Carolina. Dr. Riobe has over 900 hours of training in Chinese herbology and advanced acupuncture as well as board-certification in Integrative Medicine.
She believes that the allopathic paradigm of early diagnosis of disease to prevent death is flawed and must be changed to a paradigm of primary, not secondary prevention of diseases. She believes that the focus on early diagnosis has blocked our ability to cure cancer, and when we begin to focus on the true causes of cancer and use this information to correct metabolic errors, we will make tremendous progress against this dreadful disease. Her ground-breaking techniques have helped her to prevent diagnosis of cancer in her patients as well as prevent recurrence in patients with cancer.
Cancer is not random! Evolving mechanisms for cancer causation and prevention
My seminar will highlight old and emerging worldwide data that points to metabolic causes of cancer and not just genetics as is the current focus. A metabolic causation theory explains not only the reason we get cancer but offers strategies to treat it and prevent recurrences from a more root cause, integrative method that incorporates allopathic and integrative strategies
EVEN MORE SEMINARS
Aureli Soria-Frisch Neuroelectrics
EEG for Decision Support in Diagnosis and Prognosis
Bernhard Haas Plymouth University
Systematic Reviews: a basic guide
Dr Jorgen Sandell, PhD. Inerventions AB
Reaching the Nervous System’s Own Tools to Alleviate Movement Disabilities
Tamsin Reed Wellington Hospital, London
Maximising outcomes using advanced technology in Neurological Rehabilitation.
Xavier Golay, Ph.D. Professor of MR Neurophysics and Translational Neuroscience
Image-based biomarkers of disease progression in dementia: current and future prospects